Marlyn Mathew was named Vice President, Finance and Accounting of Zura Bio Ltd. As of November 6, 2026, Zura Bio Ltd has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 23, 2026 to May 22, 2026, naming 1 appointment and 1 departure (Form 8-K, April 23, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Zura Bio Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Zura Bio Ltd reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-23 to 2026-05-22. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Zura Bio Ltd files it.
Also on the record for Zura Bio Ltd
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Stake report, Schedule 13G/A, by Great Point Partners, LLC | 4.44% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Venrock Healthcare Capital Partners III, L.P. | 9.9% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G/A, by Suvretta Capital Management, LLC | 9.9% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by JPMORGAN CHASE & CO | 4.7% of the class | 5%+ stakes | Source |
| March 2, 2026 | Stake report, Schedule 13D/A, by AI Biotechnology LLC | 18.2% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Great Point Partners, LLC | 5.18% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by SUVRETTA CAPITAL MANAGEMENT, LLC | 8.6% of the class | 5%+ stakes | Source |
| January 27, 2026 | Stake report, Schedule 13D, by Athanor Capital | 15.7% of the class | 5%+ stakes | Source |
| January 2, 2026 | Stake report, Schedule 13G, by Athanor Capital | 15.7% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 0.4% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Great Point Partners, LLC | 5.87% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 7.13% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Zura Bio Ltd now and the warning signs.
Free to see. No signup.
Keep reading
More on Zura Bio Ltd and the records around it.
Zura Bio Ltd elsewhere on the record
- 5%+ stake filings May 2026
- Who owns it
Companies that share a holder
- AI Biotechnology LLC also filed stake reports on 3 other companies: Latigo Biotherapeutics, Inc. (Nov 2026), Yarrow Bioscience, Inc. (Jul 2026), OnKure Therapeutics, Inc. (Apr 2026)
- Great Point Partners, LLC also filed stake reports on 14 other companies: LeonaBio, Inc. (Nov 2026), Research Alliance Corporation III (Sep 2026), JATT III Acquisition Corp (Sep 2026)
- Suvretta Capital Management, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
Watch Zura Bio Ltd
Get an email when Zura Bio Ltd files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Zura Bio Ltd?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Zura Bio Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Zura Bio Ltd covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-22 | Out | Director | 2026-05-21 | 8-K, 2026-05-22 | |
| 2026-04-23 | In | Vice President, Finance and Accounting | 8-K, 2026-04-23 |
Who leads Zura Bio Ltd, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Someit Sidhu, departure reported, effective 2026-05-21 (filed 2026-05-22). No successor is named in these filings.
- Vice President, Finance and Accounting: Marlyn Mathew, appointed (filed 2026-04-23).
New leaders reset buying decisions — get the Full Report on Zura Bio Ltd: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Zura Bio Ltd, with the record behind each one.
Find candidates like Director at Zura Bio LtdEvery change, in the filing's words
Departing: Someit Sidhu, Director, effective 2026-05-21
Director Resignation On May 20, 2026, Someit Sidhu notified Zura Bio Limited (the "Company") of his decision to resign from the board of directors of the Company effective as of May 21, 2026.
- Mr. Sidhu's resignation is not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Appointed: Marlyn Mathew, Vice President, Finance and Accounting
Appointment of Principal Accounting Officer and Principal Financial Officer Also on April 20, 2026, the Board appointed Marlyn Mathew, the Company's Vice President, Finance and Accounting, as the Company's principal accounting and principal financial officer (the "Appointment").
- Transition of Chief Financial Officer On April 20, 2026, Eric Hyllengren, the Company's Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, was separated from the Company.
- Mr. Hyllengren's separation was not related to the Company's financial or operating results or to any disagreements regarding the Company's operations or financial or reporting practices.
- In connection with his separation, the Company and Mr. Hyllengren entered into a Separation Agreement on April 21, 2026.
- Mr. Hyllengren will receive severance payments in an amount equal to three months of his base salary and reimbursement for COBRA premiums for up to six months.
- All payments and benefits provided under the Separation Agreement are contingent upon the effectiveness of, and Mr. Hyllengren's continued compliance with, the Separation Agreement, and are subject to payments and benefits available through other employment or eligibility.
- In connection with the Appointment, the Board approved an increased annual base salary for Ms. Mathew of $366,415.
- Ms. Mathew, 42, serves as the Company's Vice President, Finance and Accounting, a role she has held since June 2022.
- Prior to joining the Company, Ms. Mathew was Controller at Immunovant from 2019 to May 2022, having previously served as Assistant Controller from 2018 to 2019.
Tools for this story
Each opens in a new tab, filled in for Zura Bio Ltd. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.